Nerdwallet Inc vs Pfizer Inc — how do they compare? Nerdwallet Inc trades at $9.98 (market cap $625.17M), while Pfizer Inc trades at $28.14 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 253.6× Nerdwallet Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Pfizer Inc for 158 Days on average.
| NRDS | PFE | |
|---|---|---|
Market Cap | $625.17M | $158.56B |
Volume | 1,321,316 | 44,138,282 |
Sector | Media | Health |
52-Week High | $15.93 | $29.02 |
52-Week Low | $7.58 | $23.67 |
Typical Hold Time | 45 Days | 158 Days |
Enterprise Value | $539.47M | $210.06B |
Dividend Yield | — | 6.18% |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.
Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →